Rationale for the EUCAST clinical breakpoints

First Page		Document Content
Date: 2009-12-12 17:11:17 Gram-positive bacteria Enterobacteria Staphylococcaceae Aminoglycoside Amikacin Netilmicin Tobramycin Staphylococcus aureus Staphylococcus haemolyticus Bacteria Aminoglycoside antibiotics Microbiology		Rationale for the EUCAST clinical breakpoints Add to Reading List Source URL: www.eucast.org Download Document from Source Website File Size: 118,05 KB Share Document on Facebook

	Journal of Antimicrobial Chemotherapy, 341– 352 doi:jac/dkm479 Advance Access publication 3 January 2008 Analysis of in vitro activities and modes of action of synthetic antimicrobial peptides derived DocID: 19cQ6 - View Document
	RipSeq® Single, advancing the quality of a ® bacterial reference database through DocID: 16fpJ - View Document
	Coagulase-negative staphylococci Calibration of zone diameter breakpoints to MIC values and/or resistance mechanisms Version 1.2 DocID: Snfb - View Document
	Rationale for the EUCAST clinical breakpoints DocID: Ordt - View Document
	Rationale for the EUCAST clinical breakpoints DocID: Oi4j - View Document